===============================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported) October 7, 1999
------------------------------
IMCLONE SYSTEMS INCORPORATED
- -------------------------------------------------------------------------------
(Exact name of Registrant as Specified in Charter)
Delaware 0-19612 04-2834797
- -------------------------------------------------------------------------------
(State or Other Jurisdiction (Commission File (IRS Employer
of Incorporation) Number) Identification No.)
180 Varick Street
New York, New York 10014
- -------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code (212) 645-1405
-----------------------------
Not Applicable
- -------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
<PAGE>
Item 5. Other Events.
On October 7, 1999, ImClone Systems Incorporated issued a press release, a
copy of which is attached as Exhibit 99.1 and incorporated by reference herein.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits
99.1 Press Release dated October 7, 1999.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
IMCLONE SYSTEMS
INCORPORATED
By: /s/ John B. Landes
--------------------------------
Name: John B. Landes
Title: Vice President, Business
Development and General
Counsel
October 7, 1999
<PAGE>
EXHIBIT INDEX
99.1 Press Release dated October 7, 1999.
EXHIBIT 99.1
[ImClone Systems Incorporated Letterhead]
Contact:
ImClone Systems Incorporated Burns McClellan, Inc.
Andrea F. Rabney Jonathan M. Nugent (investors)
Senior Director of Corporate Development Justin Jackson (media)
Investor Relations (212) 213-0006
For Immediate Release
IMCLONE INVESTOR CALL FOR 9:00 AM EDT OCTOBER 7, 1999
New York, NY - October 7, 1999 - ImClone Systems Incorporated's (Nasdaq: IMCL)
lead product candidate, C225, is an antibody antagonist to the Epidermal Growth
Factor receptor that is currently in Phase III clinical trials for the
treatment, in conjunction with radiation therapy or chemotherapy, of EGF
receptor positive tumors. ImClone has become aware of a U.S. patent issued to a
third party that includes claims relating to the potential use, subject to
certain restrictions, of EGF receptor antibodies in conjunction with cytotoxic
factors to inhibit tumor growth.
Outside patent counsel to the Company has indicated that, in its opinion,
ImClone will be able to commercialize C225 upon FDA approval without infringing
this third party patent.
To explain and clarify this issue ImClone will be conducting an investor
conference call at 9:00 AM EDT at 1-800-510-0141 password 1405.
ImClone Systems Incorporated, headquartered in New York, is a biopharmaceutical
company developing novel cancer therapeutic products including interventional
therapeutics, cancer vaccines and blood cell growth factors for the treatment
of cancer and cancer-related disorders.
###
